The contribution of eosinophils and the IL-23/IL-17 axis to host responses to Aspergillus
The contribution of eosinophils and the IL-23/IL-17 axis to host responses to Aspergillus
批准号:
10163121
负责人:
Stuart Michael Levitz
金额:
$41.88万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-07-11 至 2023-06-30
关键词:
AerosolsAllergicAllergic Bronchopulmonary AspergillosisAntigen PresentationAntigensAspergillosisAspergillusAspergillus fumigatusAsthmaBiologyC Type Lectin ReceptorsClinical TrialsDiseaseEpithelialEpithelial CellsFunctional disorderGeneticHumanIL17 geneImmune responseImmunityImmunocompromised HostImmunologyInfectionInterleukin-17LungLung diseasesMHC Class II GenesMeasuresMediatingModelingMorbidity - disease rateMusNatural ImmunityOrphanOutcomePathologyPersonsPhenotypePlayProductionRetinoic Acid ReceptorRoleSignal TransductionSourceT cell responseT-LymphocyteTestingadaptive immune responseadaptive immunityautocrinecellular targetingcytokinedectin 1eosinophilexperimental studyimmunological statusimmunopathologyinsightinterleukin-23mortalitymouse dectin-2mouse modelpathogenic fungusreceptorresponsetranscription factor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary/Abstract
The spectrum of diseases caused by the opportunistic fungal pathogen, Aspergillus, depends in large measure
upon the immune status of the host. Over 5 million people suffer from allergic forms of aspergillosis including
allergic bronchopulmonary aspergillosis and severe asthma with fungal sensitization. Eosinophils are hallmarks
and drivers of allergic aspergillosis but the mechanisms by which eosinophils contribute to immunopathology
are not well understood. On the other end of the spectrum, invasive aspergillosis occurs mostly in severely
immunocompromised persons; over 200,000 people annually are afflicted and the mortality rate is high. The
contribution of eosinophils to immunity in invasive aspergillosis is uncertain; however, we have observed that
mice lacking eosinophils are hypersusceptible. The IL-23/IL17 axis is postulated to play a role in immune
responses to Aspergillus species and to contribute to the pathophysiology of some forms of asthma. We have
discovered that following pulmonary challenge with live Aspergillus fumigatus conidia or aerosol challenge of
sensitized mice with A. fumigatus antigens, lung eosinophils express IL-23 and IL-17. Moreover, mice lacking
eosinophils have reduced IL-23 and IL-17 in their lungs following A. fumigatus challenge. The overarching
hypotheses of this proposal are: 1) eosinophils are major drivers of the IL-23/IL-17 axis in pulmonary
aspergillosis; and 2) eosinophilic production of IL-23 and IL-17 is protective in invasive aspergillosis but
detrimental in allergic aspergillosis. Our interrelated specific aims will test these hypotheses. Aim 1 is to
determine the drivers and consequences of eosinophil production of IL-23/IL-17 in allergic and invasive
aspergillosis. We hypothesize that eosinophil expression of IL-23 and IL-17, driven by signaling through C-type
lectin receptors, informs immunological responses and outcome in IPA and APA. Aim 2 is to assess the
contribution of IL-23R and RORγt to the phenotype of IL-17+/IL-23+ lung eosinophils elicited in response to live
Aspergillus and Aspergillus antigens. We postulate that in the setting of Aspergillus stimulation, eosinophils
respond to autocrine IL-23 via the IL-23R which turns on expression of the transcription factor RORγt leading
to IL-17 expression. Aim 3 is to elucidate cellular targets of eosinophil IL-23/IL-17 responsible for innate and
adaptive immune responses. Mechanistic insights into how eosinophil IL-23 and IL-17 expression informs
innate and adaptive immunity to Aspergillus will be garnered as we test the hypothesis that lung epithelial cells
and T cells are cellular targets of eosinophil-derived IL-17 and IL-23, respectively. Successful completion of the
proposed hypothesis-driven studies will have a large overall impact on our understanding of eosinophil biology,
the IL-23/IL-17 axis, and the immunology of invasive and allergic forms of aspergillosis. The project has
translational significance as the results could suggest rationales for clinical trials in humans with diseases
featuring eosinophil-mediated pathology.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
Dysregulated Pulmonary Inflammatory Responses Exacerbate the Outcome of Secondary Aspergillosis Following Influenza.
肺部炎症反应失调会加剧流感后继发曲霉病的结果。
DOI:
10.1101/2023.06.27.546808
发表时间:
2023
期刊:
bioRxiv : the preprint server for biology
影响因子:
--
作者:
[Lee,ChronoK, Oliveira,LorenaVN, Akalin,Ali, Specht,CharlesA, Lourenco,Diana, Gomez,ChristinaL, Ramirez-Ortiz,ZaidaG, Wang,JenniferP, Levitz,StuartM]
通讯作者:
Levitz,StuartM
A subunit Cryptococcus vaccine
-
批准号:10539210
-
项目类别:
-
资助金额:$61.98万
-
财政年份:2022
-
负责人:Stuart Michael Levitz
-
依托单位:
A subunit Cryptococcus vaccine
-
批准号:10669795
-
项目类别:
-
资助金额:$61.98万
-
财政年份:2022
-
负责人:Stuart Michael Levitz
-
依托单位:
Preclinical studies of a Cryptococcus vaccine for AIDS patients
-
批准号:10259153
-
项目类别:
-
资助金额:$79.9万
-
财政年份:2016
-
负责人:Stuart Michael Levitz
-
依托单位:
Preclinical studies of a Cryptococcus vaccine for AIDS patients
-
批准号:10557083
-
项目类别:
-
资助金额:$79.31万
-
财政年份:2016
-
负责人:Stuart Michael Levitz
-
依托单位:
Preclinical studies of a Cryptococcus vaccine for AIDS patients
-
批准号:10598929
-
项目类别:
-
资助金额:$75.38万
-
财政年份:2016
-
负责人:Stuart Michael Levitz
-
依托单位:
Preclinical studies of a Cryptococcus vaccine for AIDS patients
-
批准号:9140479
-
项目类别:
-
资助金额:$65.75万
-
财政年份:2016
-
负责人:Stuart Michael Levitz
-
依托单位:
Preclinical studies of a Cryptococcus vaccine for AIDS patients
-
批准号:9222705
-
项目类别:
-
资助金额:$64.43万
-
财政年份:2016
-
负责人:Stuart Michael Levitz
-
依托单位:
Immune Response to Cryptococcal Infections
-
批准号:8963535
-
项目类别:
-
资助金额:$49.25万
-
财政年份:2015
-
负责人:Stuart Michael Levitz
-
依托单位:
Immune Response to Cryptococcal Infections
-
批准号:9264958
-
项目类别:
-
资助金额:$49.25万
-
财政年份:2015
-
负责人:Stuart Michael Levitz
-
依托单位:
Interactions of pDCs with Aspergilus
-
批准号:8605547
-
项目类别:
-
资助金额:$40.83万
-
财政年份:2013
-
负责人:Stuart Michael Levitz
-
依托单位:
Glucan Particles as a Vaccine Platform for Protective Immunity
-
批准号:8537625
-
项目类别:
-
资助金额:$52.45万
-
财政年份:2013
-
负责人:Stuart Michael Levitz
-
依托单位:
2013 Immunology of Fungal Infections GRC and GRS
-
批准号:8451034
-
项目类别:
-
资助金额:$0.5万
-
财政年份:2013
-
负责人:Stuart Michael Levitz
-
依托单位:
Glucan Particles as a Vaccine Platform for Protective Immunity
-
批准号:8890767
-
项目类别:
-
资助金额:$54.16万
-
财政年份:2013
-
负责人:Stuart Michael Levitz
-
依托单位:
Glucan Particles as a Vaccine Platform for Protective Immunity
-
批准号:8715685
-
项目类别:
-
资助金额:$54.22万
-
财政年份:2013
-
负责人:Stuart Michael Levitz
-
依托单位:
Interactions of pDCs with Aspergilus
-
批准号:8789386
-
项目类别:
-
资助金额:$41.25万
-
财政年份:2013
-
负责人:Stuart Michael Levitz
-
依托单位:
Interactions of pDCs with Aspergilus
-
批准号:8463798
-
项目类别:
-
资助金额:$41.52万
-
财政年份:2013
-
负责人:Stuart Michael Levitz
-
依托单位:
2011 Immunology of Fungal Infections Gordon Research Conference
-
批准号:8057722
-
项目类别:
-
资助金额:$2.0万
-
财政年份:2011
-
负责人:Stuart Michael Levitz
-
依托单位:
Immunostimulatory properties of chitin and chitosan
-
批准号:8320083
-
项目类别:
-
资助金额:$20.56万
-
财政年份:2011
-
负责人:Stuart Michael Levitz
-
依托单位:
Immunostimulatory properties of chitin and chitosan
-
批准号:8071667
-
项目类别:
-
资助金额:$24.68万
-
财政年份:2011
-
负责人:Stuart Michael Levitz
-
依托单位:
Model Vaccines Exploiting Fungal Mannosylation
-
批准号:7082067
-
项目类别:
-
资助金额:$8.77万
-
财政年份:2005
-
负责人:Stuart Michael Levitz
-
依托单位:
海外基金